ATEZOLIZUMAB
atezolizumab 1.2 g/20 mL injection, 20 mL vial
ATEZOLIZUMAB (13172G)
13172G
Manner of administration:Injection
Restriction 13442
Indication: Resected early stage (Stage II to IIIA) non-small cell lung cancer (NSCLC)
Treatment phase: 1,200 mg administered once every 3 weeks
Quantities & Cost
| Max amount | # of repeats | DPMA | Max safety net | General Patient Charge |
|---|---|---|---|---|
| Max amount: 1200 mg | # of repeats: 7 | DPMA: $6,978.73 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | ||||
| Tecentriq
(atezolizumab 1.2 g/20 mL injection, 20 mL vial)
|
||||
